Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 1, 2007, Pages 123-128

  Stathopoulos, G P ^a   Malamos, N A ^b   Aravantinos, G ^c   Rigatos, S ^c   Christodoulou, Ch ^a   Stathopoulos, J ^a   Skarlos, D ^a  

^a Errikos Dunant Hospital   (Greece)

^b HELENA VENIZELOU HOSPITAL   (Greece)

^c Agii Anargyri Hospital   (Greece)

Author keywords

Paclitaxel; Pretreated ovarian cancer; Topotecan; Weekly administration

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; HYCAMPTIN; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; PATIENT COMPLIANCE; REMISSION INDUCTION; THROMBOCYTOPENIA; TOPOTECAN; TREATMENT OUTCOME;

EID: 34247374705     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0383-6     Document Type: Article

References (28)

1. McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6
2. Piccart MJ, Bertelsen K, James K et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92:699-708
3. McGuire WP, Ozolos RF (1998) Chemotherapy of advanced ovarian cancer. Semin Oncol 25:340-348
4. Kudelca AP, Tresukosol D, Edwards CL et al (1996) Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557
5. Creemers GJ, Bolis G, Gore M et al (1996) Topotecan an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 12:3056-3061
6. ten Bokkel Huinink W, Gore M, Carmichael J et al (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial. J Clin Oncol 15:2183-2193
7. Bookman MA, Malmstrom H, Bolis G et al (1998) Topotecan for the treatment of advanced epithelial ovarian cancer: an open label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345-3352
8. Hoskins P, Eisenhower E, Beare S et al (1998) Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 16:2233-2237
9. Ardizzoni A, Hansen H, Dombernowsky P et al (1997) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090-2096
10. Belinson J, Kennedy A, Webster K et al (1999) Preliminary results of a Cleveland Clinic Cancer Center Gynecologic Oncology Program phase 2 trial of topotecan administered on a 3-day schedule as salvage therapy of platinum and paclitaxel refractory ovarian cancer. Proc Am Soc Clin Oncol 18:369a
11. Franci G, Panza N, Comella P et al (1999) Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Ann Oncol 10:355-361
12. Frasci G, Nicolella G, Comella P et al (2001) A weekly regimen of cisplatin, paclitaxel and topotecan with granulocytecolony stimulating factor support for patients with extensive disease small-cell lung cancer: a phase II study. Br J Cancer 84:1166-1172
13. Homesley H, Bemigno B, Williams J et al (2001) Weekly topotecan combined with weekly paclitaxel in second or third-line therapy of epithelial ovarian carcinoma. Proc Soc Clin Oncol 20:191b
14. Klaasen V, Wilke H, Strumberg D et al (1996) Phase I study with a weekly 1-h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 32A:547-551
15. Stathopoulos GP, Rigatos SK, Christodoulou C et al (2004) Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Cancer Chemother Pharmacol 54:259-264
16. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
17. Miller AB, Hoogstraten B, Stagnet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
18. Bolis G, Scarfone G, Tateo S et al (2001) Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel. Gynecol Oncol 80:13-15
19. Gore M, Oza A, Rustin G et al (2002) A randomized trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 38:57-63
20. Bhoola SM, Coleman RL, Herzog T et al (2004) Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian Cancer. Gynecol Oncol 95:564-569
21. Markman M, Hall J, Spitz D et al (2002) Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel refractory ovarian cancer. J Clin Oncol 20:2365-2369
22. Morris R, Munkarah A (2002) Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. Oncologist 7(suppl 5):29-35
23. Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322
24. Armstrong DK (2002) Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7(suppl 5):20-28
25. Gore M, ten Bokkel Huinink W, Carmichael J et al (2001) Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 19:1893-1900
26. Schiller JH, Adak S, Cella D et al (2001) Topotecan vs observation after cisplatin plus etoposide in extensive stage SCLC E7593 - a phase III trial of the Eastern Cooperative Group. J Clin Oncol 19:2114-2122
27. Rowinsky EK (2002) Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule? Oncologist 7:324-329
28. Levy T, Inbar M, Menczer J et al (2004) Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 95:686-690